Proteasome inhibitors: a novel class of potent and effective antitumor agents. - Wikidata - awgldk - TriplyDB

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

http://www.wikidata.org/entity/Q33864458

about

Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons Why bortezomib cannot go with 'green'?Multiple myeloma Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis New molecularly targeted therapies for lung cancer Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells Investigations of methylmercury-induced alterations in neurogenesis The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection Thrombotic microangiopathy associated with proteasome inhibitors Modulatory effects of bortezomib on host immune cell functions Advances in the understanding of mechanisms and therapeutic use of bortezomib Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Boron chemicals in diagnosis and therapeutics Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit Complementary whole-genome technologies reveal the cellular response to proteasome inhibition by PS-341 Systematic approaches to identify E3 ligase substrates Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Trial Watch: Proteasomal inhibitors for anticancer therapy Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation Proteasome function is required for platelet production PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer The ubiquitin-proteasome pathway and proteasome inhibitors Novel CD20 monoclonal antibodies for lymphoma therapy Activation of mutant enzyme function in vivo by proteasome inhibitors and treatments that induce Hsp70 Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells Identification of genes affecting the toxicity of anti-cancer drug bortezomib by genome-wide screening in S. pombe Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes

P2860

Q21090814-ADF1211D-9E68-48FD-8A90-DF642E265E97 Q21195237-EDB67EEA-A7CB-45F0-B608-44260EBB2105 Q24301844-217FEDB0-21E2-41E8-9214-C8AB957BA2D0 Q24630709-3988076C-811F-44FD-A81A-55D7E858E4D8 Q24655964-6D4FDD9D-E013-4E25-96CA-FF561C887F92 Q24675778-04FD28F7-4EF0-4B3B-A7FB-1E57AC34362B Q24676117-5395AF59-B381-4A50-9334-1E9FE2B0219B Q24680988-3AD1873A-186D-4779-B45C-A4668160CFB8 Q24681630-42023950-6FCD-4F40-9EE4-F48BDF351B64 Q24794927-C3611062-BFDE-4C93-9CDE-73D402EC977A Q24806463-A60735B7-5560-4471-AB02-4F4DA4C2F982 Q24812651-33E0C660-2982-4280-97EF-953F7D993742 Q24813108-D92BA073-6AE0-4F19-9755-7F3A77E09538 Q24814325-7BAF2C1F-CBB6-4CF1-A09F-D078801E9F74 Q26252076-8E11CB1F-015B-41A4-8521-40E6723ED71E Q26785826-40CCF3B7-2AB8-4699-A1CD-20E3B0ABDAA9 Q26795618-8925F735-DF51-45F1-8A43-D8699C25582B Q26849940-02543460-8837-48E5-A215-AD570D8602B3 Q26860284-CC988C1E-98B5-4C6A-BD55-1123B182A529 Q27004421-662943C8-A753-4CDE-B78C-AB6565640E1F Q27006075-03066539-9635-46CD-9532-B9ACEB20BC24 Q27663486-2046F181-1D7A-4800-932E-0B6D422D5DE7 Q27936558-71461D76-5732-4EC8-B243-BC47B814E90A Q28068398-95EA04C4-EB5A-421A-B97A-632C59EA5C56 Q28075606-B0B7BEC9-B1D0-47BF-AA1D-236F88E653C6 Q28082910-4B6866DA-AE55-4740-963C-5F61A8F44C5B Q28141769-A3DD1A73-579E-4EBC-B8B4-495D820E8015 Q28244689-EC8FF261-52DF-41E5-9F9A-DAA6FB88A5F4 Q28267716-3B669726-C7F7-4707-BF6A-17396120A50A Q28367002-CB897A8B-1AC1-4AF9-94CC-A59945D25909 Q28390112-13C79E9E-816E-4AC2-9D0D-C79D0CF55B5D Q28472376-F1198E8C-7137-4DA7-B8ED-9F9CA613EE41 Q28475914-5A36E1DC-677D-4FB2-82E0-CDFCB11CCDA5 Q28478963-7D85DDE4-EDAB-4D3E-84FB-C7BF31DB1C23 Q28533426-8FFC5ED9-93B1-48AA-834B-3DB33ECFF323 Q28533949-FC6A3C75-2ECE-4E25-9B38-32ED9C836807 Q28534042-A6607810-C3D1-43AD-B282-82F4C3FBA430 Q28534151-1731BBBE-5237-4119-9154-410CB69DA643 Q28534703-BF3A9C8C-6B4D-4084-8DC1-E9DC0F1263DB Q28542496-D83D5572-8FAA-4BAB-B8EA-131763F03BA8

P2860

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

http://www.wikidata.org/entity/Q33864458

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունիսին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

@ast

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

@en

type

label

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

@ast

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

@en

prefLabel

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

@ast

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

@en

P1433

Q33864458-414A2DFE-3188-43C1-8251-F5C8FA43D5D4

P1476

Q33864458-FA703C69-163B-43B5-8119-CF3B2CA53C76

P2093

Q33864458-12DA248C-636A-409B-9FC4-8182FE943E3C

Q33864458-213C0036-17C3-4D55-8B3F-8FB92F99315A

Q33864458-33589F24-54D2-4E12-BBCC-27D147550BD3

Q33864458-555B4F82-4AA4-4943-84A4-C15EF180E871

Q33864458-563C26B3-7028-46EC-9449-EE9907F2C616

Q33864458-68C5570B-7834-4D54-ADD5-A02BA8EF9DB2

Q33864458-81C3BDA3-BB1A-4843-B4E5-E379B5683E0A

Q33864458-C9A3D49B-EF82-440C-A0F7-7B657422C320

Q33864458-DCBDD1E2-97F4-4B52-B7DD-E3F5A2D447F7

Q33864458-E0706DBB-9E47-497C-98C9-7513E77C0E30

P304

Q33864458-6A93344F-1760-4BE7-83D9-75645F13D91D

P31

Q33864458-1A880921-F77B-40D9-A916-A3E932CC759F

P407

Q33864458-F3A42FF8-670B-472C-A1F0-AD837A98A5A4

P433

Q33864458-4D320C81-3105-415A-BC68-2EB840A11C42

P478

Q33864458-11780D02-87EE-4D6C-894B-4B03896F10A3

P577

Q33864458-390D5F34-6050-4B8B-B85D-7A34CA53AC2F

P698

Q33864458-6991C206-60D9-47EF-A23C-D90F68D99CBA

P1433

Cancer Research

P1476

Proteasome inhibitors: a novel class of potent and effective antitumor agents

@en

P2093

A Destree

http://www.w3.org/2001/XMLSchema#string

C S Pien

http://www.w3.org/2001/XMLSchema#string

D D Lazarus

http://www.w3.org/2001/XMLSchema#string

E A Sausville

http://www.w3.org/2001/XMLSchema#string

J Adams

http://www.w3.org/2001/XMLSchema#string

J Johnson

http://www.w3.org/2001/XMLSchema#string

J Maas

http://www.w3.org/2001/XMLSchema#string

P J Elliott

http://www.w3.org/2001/XMLSchema#string

S Prakash

http://www.w3.org/2001/XMLSchema#string

V J Palombella

http://www.w3.org/2001/XMLSchema#string

P304

2615-2622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10363983

http://www.w3.org/2001/XMLSchema#string